JP2018522854A5 - - Google Patents

Download PDF

Info

Publication number
JP2018522854A5
JP2018522854A5 JP2017566077A JP2017566077A JP2018522854A5 JP 2018522854 A5 JP2018522854 A5 JP 2018522854A5 JP 2017566077 A JP2017566077 A JP 2017566077A JP 2017566077 A JP2017566077 A JP 2017566077A JP 2018522854 A5 JP2018522854 A5 JP 2018522854A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
oral pharmaceutical
composition according
pharmaceutically acceptable
acceptable carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017566077A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018522854A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/038822 external-priority patent/WO2016210003A2/en
Publication of JP2018522854A publication Critical patent/JP2018522854A/ja
Publication of JP2018522854A5 publication Critical patent/JP2018522854A5/ja
Pending legal-status Critical Current

Links

JP2017566077A 2015-06-22 2016-06-22 １７−ヒドロキシプロゲステロンエステル含有経口組成物及び関連方法 Pending JP2018522854A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562183031P 2015-06-22 2015-06-22
US62/183,031 2015-06-22
US201662295951P 2016-02-16 2016-02-16
US62/295,951 2016-02-16
PCT/US2016/038822 WO2016210003A2 (en) 2015-06-22 2016-06-22 17-hydroxyprogesterone ester-containing oral compositions and related methods

Publications (2)

Publication Number Publication Date
JP2018522854A JP2018522854A (ja) 2018-08-16
JP2018522854A5 true JP2018522854A5 (https=) 2019-07-25

Family

ID=57586205

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017566077A Pending JP2018522854A (ja) 2015-06-22 2016-06-22 １７−ヒドロキシプロゲステロンエステル含有経口組成物及び関連方法

Country Status (12)

Country Link
US (3) US20170035781A1 (https=)
EP (1) EP3310359B1 (https=)
JP (1) JP2018522854A (https=)
CN (1) CN107847506A (https=)
AU (1) AU2016284459B2 (https=)
BR (1) BR112017027688A2 (https=)
ES (1) ES3005883T3 (https=)
IL (1) IL256493A (https=)
MX (1) MX2017016823A (https=)
PH (1) PH12017502416A1 (https=)
WO (1) WO2016210003A2 (https=)
ZA (1) ZA201801692B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109219442A (zh) 2016-04-04 2019-01-15 Omeza有限公司 鱼油局部组合物
PE20211285A1 (es) * 2018-11-27 2021-07-19 Bayer Ag Proceso para la produccion de formas farmaceuticas que contienen inhibidores de los canales task-1 y task-3 y su uso para la terapia de trastornos respiratorios
CN109662953B (zh) * 2019-02-18 2022-05-10 威海金思力生物科技股份有限公司 一种维生素d软胶囊及其制作方法
WO2021081276A1 (en) * 2019-10-23 2021-04-29 Slayback Pharma Llc Stable pharmaceutical compositions containing estradiol and progesterone for oral administration
CN111135153B (zh) * 2020-01-21 2025-08-19 安士制药（中山）有限公司 一种熊去氧胆酸胶囊及其制备方法
CN113616660A (zh) * 2020-05-07 2021-11-09 深圳埃格林医药有限公司 孕激素制剂及其用途
US12502396B2 (en) * 2020-10-27 2025-12-23 Lipocine Inc. Hydroxyprogesterone caproate compositions and methods of use in preventing preterm birth
US11370811B1 (en) 2020-11-20 2022-06-28 Lipocine Inc. (17-)-3-oxoandrost-4-en-17-yl dodecanoate compositions and methods of preparation and use
US11969434B1 (en) 2022-08-29 2024-04-30 Lipocine Inc. Oral allopregnanolone compositions and methods of use
IT202100013898A1 (it) * 2021-05-27 2022-11-27 Hulka S R L Composizione comprendente un estere di alfa-tocoferolo per la riduzione del rischio di parto pretermine
CN116077416B (zh) * 2021-11-05 2024-12-06 深圳埃格林医药有限公司 一种包含孕激素的口服制剂及制备方法和应用
WO2024023173A1 (en) * 2022-07-27 2024-02-01 Ipsico Ug Solid pharmaceutical dosage form comprising a bcs class ii drug and a method for producing the same
US12186327B2 (en) 2022-08-29 2025-01-07 Lipocine Inc. Oral allopregnanolone compositions and methods of use
US12589135B2 (en) * 2023-08-21 2026-03-31 Cmpd Licensing, Llc Topical administration of GLP-1 receptor agonists

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3164520A (en) 1962-10-29 1965-01-05 Olin Mathieson Injectable steroid compositions containing at least 75% benzyl benzoate
NL151903B (nl) 1965-03-24 1977-01-17 Schering Ag Werkwijze ter bereiding van een injectievloeistof door een steroid op te lossen in een mengsel van ricinusolie en benzylbenzoaat.
FR2408345A1 (fr) 1976-11-30 1979-06-08 Besins Jean Louis Nouvelle composition a action anti-conceptionnelle
US4230702A (en) 1978-01-09 1980-10-28 Kali-Chemie Pharma Gmbh Readily enterally absorbable pharmaceutical compositions of per se poorly enterally absorbable pharmacologically active agents
US4439432A (en) 1982-03-22 1984-03-27 Peat Raymond F Treatment of progesterone deficiency and related conditions with a stable composition of progesterone and tocopherols
US5314882A (en) 1984-01-03 1994-05-24 International Foundation For Biochemical Endocrinology Method for promoting growth and improved meat quality in meat producing animals with female steroidal hormones
US5140021A (en) 1986-04-16 1992-08-18 Genesis Systems Corporation Method and dosage form for treatment of premenstrual syndrome
GB8730011D0 (en) 1987-12-23 1988-02-03 Smithkline Dauelsberg Pharmaceutical compositions
AU5157590A (en) 1989-02-06 1990-08-24 Abbott Laboratories Pharmaceutical compositions for oral administration
IT1252867B (it) 1991-12-31 1995-06-28 Gentili Ist Spa Composizioni farmaceutiche contenenti progesterone ad elevata biodisponibilita'
DK95093D0 (da) 1993-08-20 1993-08-20 Novo Nordisk As Farmaceutisk formulering indeholdende et hormon
US5543150A (en) 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5633011A (en) * 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
EP0777491B1 (de) 1994-08-23 2004-11-17 Deutsche Gelatine-Fabriken Stoess AG Verwendung von geschmacksneutralem, hydrolysiertem kollagen und mittel enthaltend dasselbe
DE19718012C1 (de) 1997-04-29 1998-10-08 Jenapharm Gmbh Verfahren zur Herstellung peroral anwendbarer fester Arzneiformen mit gesteuerter Wirkstoffabgabe
DE19739916C2 (de) 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
FR2772617B1 (fr) 1997-12-19 2001-03-09 Besins Iscovesco Lab Comprime de progesterone et son procede de preparation
FR2775599B1 (fr) 1998-03-09 2001-08-17 Besins Iscovesco Lab Composition pharmaceutique a base de progesterone naturelle de synthese et d'oestradiol et son procede de preparation
US6602521B1 (en) 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
US6214815B1 (en) 1998-12-23 2001-04-10 Ortho-Mcneil Pharmaceuticals, Inc. Triphasic oral contraceptive
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
GB9907715D0 (en) 1999-04-01 1999-05-26 Scherer Corp R P Pharmaceutical compositions
US20030236236A1 (en) 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US20020131988A1 (en) 1999-12-16 2002-09-19 Foster Todd P. Pharmaceutical implant containing immediate-release and sustained-release components and method of administration
US6544553B1 (en) 1999-12-28 2003-04-08 Watson Pharmaceuticals, Inc. Dosage forms and methods for oral delivery of progesterone
US20040022862A1 (en) 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
FR2818905A1 (fr) 2000-12-28 2002-07-05 Cll Pharma Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile
FR2821555B1 (fr) 2001-03-01 2003-05-16 Besins Int Lab Progestatif co-micronise avec un tensioactif, composition pharmaceutique le comprenant, leurs procedes de fabrication et leurs utilisations
FR2832065B1 (fr) 2001-11-13 2004-11-05 Besins Int Belgique Composition pharmaceutique a base de progesterone micronisee son procede de preparation et ses utilisations
EP1482946A1 (en) 2002-03-14 2004-12-08 Watson Pharmaceuticals, Inc. Progesterone oral drug delivery system
US8216609B2 (en) 2002-08-05 2012-07-10 Torrent Pharmaceuticals Limited Modified release composition of highly soluble drugs
CN1231210C (zh) 2002-08-20 2005-12-14 杭州容立医药科技有限公司 黄体酮胶囊组合物及其制备方法
CN1678324A (zh) 2002-08-28 2005-10-05 罗伯特·卡斯珀 雌激素替代治疗方案
ES2338782T3 (es) 2002-09-05 2010-05-12 Pantarhei Bioscience B.V. Composicion farmaceutica oral que comprende 15-hidroxitestosterona y derivados.
JP2004155780A (ja) 2002-10-16 2004-06-03 Taisho Pharmaceut Co Ltd 生活習慣病改善剤組成物
ATE482695T1 (de) 2002-12-13 2010-10-15 Durect Corp Orale darreichungsform mit flüssigen hochviskosen trägersystemen
CN1282459C (zh) 2002-12-24 2006-11-01 上海医药工业研究院 黄体酮胶丸及制备方法
US20040266025A1 (en) * 2003-02-06 2004-12-30 Durlin Hickok Screening and treatment methods for prevention of preterm delivery
GB0305941D0 (en) 2003-03-14 2003-04-23 Camurus Ab Composition
CN1299686C (zh) 2003-04-03 2007-02-14 上海医药工业研究院 黄体酮半固体骨架制剂的组合物
CN1623550A (zh) * 2003-12-04 2005-06-08 张伟 己酸羟孕酮口服制剂和用途
CA2548281C (en) 2003-12-09 2013-11-12 Medcrystalforms, Llc Method of preparation of mixed phase co-crystals with active agents
CN1933873A (zh) 2004-03-19 2007-03-21 沃纳奇尔科特公司 延长周期的多相口服避孕方法
GT200500186A (es) 2004-07-07 2006-03-02 Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits
US7473687B2 (en) 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
US8663681B2 (en) 2005-05-26 2014-03-04 Teva Women's Health, Inc. Oral dosage forms comprising progesterone and methods of making and using the same
US8828981B2 (en) * 2007-02-06 2014-09-09 George Creasy Progesterone for the treatment or prevention of spontaneous preterm birth
SI2200588T1 (sl) 2007-09-25 2019-08-30 Solubest Ltd. Sestavki, ki obsegajo lipofilne aktivne spojine, in postopek za njihovo pripravo
CA2744906A1 (en) 2007-11-29 2009-06-04 Gregg A. Jackson Progesterone-containing compositions and devices
WO2010117873A2 (en) 2009-04-06 2010-10-14 Banner Pharmacaps, Inc. Progesterone solutions for increased bioavailability
CA2779270A1 (en) 2009-10-29 2011-05-05 The Trustees Of The University Of Pennsylvania Method of predicting risk of preterm birth
US20110152840A1 (en) 2009-12-23 2011-06-23 Drugtech Corporation Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions
US20110262502A1 (en) * 2010-02-08 2011-10-27 Prairie Pharmaceuticals LLC Pulmonary delivery of 17-hydroxyprogesterone caproate (17-hpc)
CA2789238C (en) 2010-03-09 2020-05-12 Dignity Health Methods for inhibiting preterm labor and uterine contractility disorders and preventing cervical ripening
US20110312928A1 (en) 2010-06-18 2011-12-22 Lipocine Inc. Progesterone Containing Oral Dosage Forms and Related Methods
US20110312927A1 (en) 2010-06-18 2011-12-22 Satish Kumar Nachaegari Progesterone Containing Oral Dosage Forms and Related Methods
US9375437B2 (en) 2010-06-18 2016-06-28 Lipocine Inc. Progesterone containing oral dosage forms and kits
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US8951996B2 (en) * 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods

Similar Documents

Publication Publication Date Title
JP2018522854A5 (https=)
JP3382940B2 (ja) 中枢ドパミン欠乏状態を治療するための経口投与可能な医薬製剤
JP6827962B2 (ja) 過剰体重に影響される女性患者のためのドロスピレノン系避妊薬
WO2012055840A1 (en) Composition and preparation for treatment of dysmenorrhea and menstrual pain and use of a hormonal agent and a zinc salt for treatment of menstrual disorders
EA028680B1 (ru) Фармацевтическая композиция, содержащая дроспиренон, и набор для предупреждения зачатия
US20120053160A1 (en) Dosage Form for Hormonal Contraception
KR20230005239A (ko) 경구 투여용 신규한 지연 방출 조성물
WO2024121800A1 (en) Extended-release pharmaceutical compositions of dydrogestrone
KR20240148359A (ko) 특발성 폐섬유증 치료를 위한 불록시부티드의 용도
TWI351960B (en) Multiphase product for contraception based on a na
US10688072B2 (en) Misoprostol dispersible tablet
HU212428B (en) Process to prepare pharmaceutical compositions containing gemfibrozyl
Nelson et al. A global, randomized, phase III, pearl index study comparing the efficacy and safety of two low-dose levonorgestrel-releasing intrauterine systems (LNG-IUSS) in nulliparous and parous women
TW201420103A (zh) 包含左炔諾孕酮（ｌｅｖｏｎｏｒｇｅｓｔｒｅｌ）及ｃｏｘ抑制劑之醫藥組合物於「依需求（ｏｎ ｄｅｍａｎｄ）」避孕之用途及應用療法
NZ739324A (en) 17-hydroxyprogesterone ester-containing oral compositions and related methods
NZ739324B2 (en) 17-hydroxyprogesterone ester-containing oral compositions and related methods
CA2954086C (en) Misoprostol dispersible tablet
EP3108889A1 (en) Drospirenone-based contraceptive for a female patient affected with excess weight
ES2777886T3 (es) Composición farmacéutica que comprende drospirenona y kit anticonceptivo
Saini et al. Comparative effectiveness of simultaneous administration of mifepristone and misoprostol versus interval regimen of mifepristone followed by misoprostol 12 hours apart in second trimester medical abortion
CN106265694A (zh) 用于过重女性患者的基于屈螺酮的避孕药
HK40096856A (zh) 新的改良释放的口服避孕组合物
Contraceptive et al. PrOVRAL® 21
Start 1 INDICATIONS AND USAGE
OA18512A (en) Drospirenone-based contraceptive for a female patient affected with excess weight.